ProCE Banner Activity

Activity of ADCs in Clinical Trials for Lung Cancer: Anti-HER2/HER3 ADCs

Slideset Download
Download these slides from a live CCO Webinar to review the latest clinical trial data on ADCs in NSCLC, including activity in HER2-amplified or mutant lung cancers, as well as in HER3-expressing, EGFR-mutatant NSCLC.

Released: April 08, 2021

Expiration: April 07, 2022

No longer available for credit.

Share

Faculty

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York